Laura B. Pincus

Guest Editor for the following articles:

Mar
2018
Vol. 37. No. 1

Introduction

Laura B. Pincus, MD
One theme that runs through many of the articles is the advent of targeted therapies. As the community has gained a greater comprehension of the pathogenesis behind many of these diseases, the development of these targeted therapies has become possible.
MORE
Mar
2018
Vol. 37. No. 1

Mycosis fungoides—clinical and histopathologic features, differential diagnosis, and treatment

Lorenzo Cerroni, MD
Conventional systemic chemotherapy and single-agent chemotherapy (eg, gemcitabine) give usually good results in advanced MF, but recurrences are the rule. Monoclonal antibodies directed against cluster of differentiation (CD)52 (alemtuzumab), CD30 (brentuximab vedotin), and chemokine receptor 4 (CCR4; mogamulizumab), as well as several other experimental therapies, have shown promising results and represent a valid alternative.
MORE